Table 5. Top Five Canonical Pathways.
Significance (p-value) of pathways is determined by Fischer's exact test of probability of genes in the dataset fit into the pathway by chance alone and by proportion (ratio) of genes in pathway that are included in the dataset (# genes).
Tissue | Ingenuity canonical pathways | –log(p) | Ratio | # genes |
---|---|---|---|---|
Retina/RPE | Atherosclerosis signaling | 3.99 | 1.09E-01 | 14 |
LXR/RXR activation | 3.25 | 9.56E-02 | 13 | |
p38 MAPK signaling | 3.25 | 1.13E-01 | 12 | |
MIF regulation of innate immunity | 3.15 | 1.40E-01 | 7 | |
Hepatic fibrosis/hepatic stellate cell activation | 3.14 | 9.52E-02 | 14 | |
Choroid | Axonal guidance signaling | 7.03 | 2.98E-01 | 128 |
Molecular mechanisms of cancer | 5.55 | 2.88E-01 | 109 | |
CXCR4 signaling | 5.33 | 3.39E-01 | 57 | |
Ephrin receptor signaling | 5.09 | 3.12E-01 | 62 | |
EIF2 signaling | 4.85 | 3.22E-01 | 66 | |
Sclera | ATM signaling | 5.31 | 2.20E-01 | 13 |
Role of CHK proteins in cell cycle Checkpoint control | 3.68 | 2.29E-01 | 8 | |
Atherosclerosis signaling | 3.53 | 1.24E-01 | 16 | |
Mitotic roles of polo-like kinase | 2.37 | 1.38E-01 | 9 | |
Cell cycle: G2/M DNA damage Checkpoint regulation | 2.17 | 1.43E-01 | 7 | |
Optic Nerve | Wnt/β-catenin signaling | 5.61 | 2.03E-01 | 35 |
Hereditary breast cancer signaling | 4.99 | 2.05E-01 | 26 | |
Human embryonic stem cell pluripotency | 4.58 | 1.80E-01 | 27 | |
Cell cycle: G1/S checkpoint regulation | 3.64 | 2.31E-01 | 15 | |
RAR activation | 3.47 | 1.60E-01 | 30 | |
Cornea | Breast cancer regulation by Stathmin1 | 6.67 | 2.93E-01 | 61 |
Mitochondrial dysfunction | 6.35 | 2.64E-01 | 46 | |
Wnt/β-catenin signaling | 6.16 | 3.14E-01 | 54 | |
Axonal guidance signaling | 5.89 | 2.37E-01 | 102 | |
Molecular mechanisms of cancer | 5.79 | 2.41E-01 | 91 |